US Pharma MarketingTo analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
Source: BioPharma Dive